# CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)

> **NCT02047175** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 64 (actual)

## Conditions studied

- Hypertension
- Hyperlipidemia

## Interventions

- **DRUG:** Telmisartan/S-Amlodipine
- **DRUG:** Rosuvastatin
- **DRUG:** Telmisartan/S-Amlodipine + Rosuvastatin
- **DRUG:** Telmisartan/S-Amlodipine + Rosuvastatin

## Key facts

- **NCT ID:** NCT02047175
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2014-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02047175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02047175, "CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02047175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*